

# INTRODUCTION TO ODIN'S LEGAL FRAMEWORK

---

## ABOUT THIS DOCUMENT

This document provides an overview of the legal documents in ODIN and explains how these legal documents complement each other. The document is aimed for legal professionals, business developers, technology transfer professionals, grant receivers, and others associated with an ODIN grant.

You can find all listed agreements on the ODIN website. Should you have any questions about the legal framework please contact:

ODIN Program Coordinator, **Chantelle Dana Driever:**  
cdd@au.dk, 2214 7048

ODIN Administrative Coordinator, **Ditte Høyer Engholm:**  
dhe@au.dk, 9350 8736

ODIN is sponsored by the Novo Nordisk Foundation (Grant number: NNF23SA0088590) and anchored at and operated by the Open Innovation in Science Center at AU in the period 2024-2028. As ODIN is a time-limited platform, a legal framework has been established to ensure a streamlined project start for funded research projects. The structure of ODIN's legal framework is described in more detail on the following page.

## ABOUT ODIN

ODIN is an Open Innovation in Science platform that focuses on open research collaborations. ODIN brings together international stakeholders from industry and academia to co-create and co-execute research projects which accelerate innovation, mainly within drug discovery and diagnostics. The current platform was established by five Danish universities together with a range of Danish and international companies within pharma and biotech, and it builds on a 3-year pilot platform from Aarhus University.

ODIN is a cascade funding platform that differs significantly from traditional research platforms. ODIN offers an open, IP-free process where knowledge, ideas, and materials can be freely shared between academia, industry, and societal actors to generate new insights. As all results must be shared openly, anyone may utilise and further develop the results for commercial purposes downstream. This open process is known to enhance problem solving and accelerate innovation, thereby fostering a more agile translation of research results into novel solutions and technologies for addressing unmet societal needs.

Partners in ODIN are listed on the last page.

## GRANT AGREEMENT

The GA has been entered into between the grantor (the Novo Nordisk Foundation) and grantee (Aarhus University).


The GA stipulates the overall terms and conditions for the ODIN platform grant and it takes precedence over all agreements in the ODIN legal framework.

## PROJECT AGREEMENT

When a project is granted by ODIN, the **non-negotiable PA** must be entered into between all parties involved in that individual research project.

The PA stipulates the terms and conditions for the project parties in each research project. The template is based on a standard research collaboration agreement detailing the specific open terms of ODIN, including no restrictive IP (universal access rights to foreground knowledge) and openness regarding all results and data derived from the project.

See the next page for more information on the PA.



## FRAMEWORK AGREEMENT

The FA has been entered into between the 18 ODIN partners. The FA stipulates the organisation of the ODIN platform including the call process, governance, confidentiality and liability. New organisations may wish to accede to the FA in order to be a partner in the ODIN platform and become involved in the governing organs of ODIN. Should you have any questions regarding accession, please reach out to the ODIN secretariat.

## DECISION LETTER

The DL is issued by the ODIN Secretariat to the main applicant for each of the individual projects granted by ODIN. The DL contains a summary of important project details as listed in the PA, regarding e.g. payment terms, reporting and communication activities. The DL is for information only and does not need to be signed by the project parties.

## ADDITIONAL INFO ON THE PA

The project parties in the PA may include universities, hospitals, other non-profit institutions, and for-profit organizations.

### **The Project Agreement template is non-negotiable:**

To ensure ease of collaboration and early start of the projects, the PA has been pre-negotiated by the 18 ODIN Partners listed to the right as part of the Framework Agreement. Therefore, the PA template is non-negotiable.

### **Signing of the Project Agreement**

The main applicant for each granted project is responsible for filling out the project-specific information in the PA and for the collection of signatures amongst the project parties. The PA must be signed by a legal signatory authority from each of the project parties' organizations (in accordance with each party's own delegation rules) before the funding is transferred to the main applicant.

## PARTNERS IN ODIN

The ODIN platform is a joint project between the 5 Danish universities and 13 pharma and biotech companies of varying sizes.

### **The universities are:**

- University of Copenhagen (KU)
- Technical University of Denmark (DTU)
- Aalborg University (AAU)
- University of Southern Denmark (SDU)
- Aarhus University (AU)

### **The 13 company partners are:**

- Novo Nordisk
- H. Lundbeck
- Roche Pharmaceuticals
- Bayer
- AstraZeneca
- DeepCure
- UNIKUM Therapeutics
- Mmimetika Biosciences
- Kriptonite Therapeutics
- omiics
- Charles River Laboratories
- Nordic Bioscience
- PentaBase



OPEN DISCOVERY  
INNOVATION NETWORK

A Novo Nordisk Foundation Sponsored Initiative